International Clinical Neuroscience Journal

Vol. 9 (2022)

Stereotactic Iodine-125 Brachytherapy for Low-Grade Glioma Treatment: A Monte Carlo study

International Clinical Neuroscience Journal, Vol. 9 (2022), 10 January 2022 , Page e9

Abstract

Background: Stereotactic brachytherapy is an appropriate method that has been used for brain tumors and metastases treatment for more than 40 years for many patients in the world. Also, iodine-125 brachytherapy has been utilized in brain tumors for interstitial brachytherapy treatment since 1979. Even though the physical and biological features make these implants particularly attractive for minimal invasive treatment, the main goal of this paper is to evaluate the I-125 seed time and dose reached to brain glioma tumors of different sizes for treatment using Monte Carlo modeling.
Methods: In this paper, Monte Carlo simulation has been applied by the Gate code with 20 (MBq) activity for an iodine seed design for low-grade glioma tumors treatment. Dosimetry features of this source were defined by the updated TG-43U1 recommendations. The absorbed dose distribution around the seed was calculated using the Gate code in liquid water.
Result: The ideal condition for brachytherapy is for tumors smaller than 4 cm. With a larger tumor size, the absorption dose at the border of tumor and healthy tissue will be decreased and the implantation time for seeds will increase.
Conclusion: Placing an iodine-125 source inside the tumor is not sufficient because of the non-uniform dose distribution in the tumor and the length of treatment time. Using four iodine-125 sources eliminates the tumor, and also, a uniform dose distribution is created in the tumor and the implantation time will be reduced, respectively.

Keywords:
  • Brachytherapy; Tumor; Iodine-125; Gate code simulation.

How to Cite

1.
Valizadeh S, Saeedzadeh E, Zali A, Nedaei H, Zare Ganjaroodi S. Stereotactic Iodine-125 Brachytherapy for Low-Grade Glioma Treatment: A Monte Carlo study. Int Clin Neurosci J [Internet]. 2022 Feb. 6 [cited 2026 Jul. 25];9:e9. Available from: https://journals.sbmu.ac.ir/neuroscience/article/view/36377

References

Han S. Brain Tumor. Healthline; 2017.

Litin SC. Mayo Clinic Family Health Book. 5th ed. Mayo Clinic Press; 2018.

Fisher PG, Carson BS. Management of brainstem gliomas in children. Contemp Neurosurg. 1996;18(24):1-6.

White HH. Brain stem tumors occurring in adults. Neurology. 1963;13:292-300. doi: 10.1212/wnl.13.4.292.

Jallo GI, Biser-Rohrbaugh A, Freed D. Brainstem gliomas. Childs Nerv Syst. 2004;20(3):143-53. doi: 10.1007/s00381- 003-0870-6.

Freeman CR, Farmer JP. Pediatric brain stem gliomas: a review. Int J Radiat Oncol Biol Phys. 1998;40(2):265-71. doi: 10.1016/s0360-3016(97)00572-5.

Hong S, Kim IH, Wang KC. Outcome and prognostic factors of childhood diffuse brainstem glioma. Cancer Res Treat. 2005;37(2):109-13. doi: 10.4143/crt.2005.37.2.109.

Sandri A, Sardi N, Genitori L, Giordano F, Peretta P, Basso

ME, et al. Diffuse and focal brain stem tumors in childhood: prognostic factors and surgical outcome. Experience in a single institution. Childs Nerv Syst. 2006;22(9):1127-35. doi: 10.1007/s00381-006-0083-x.

Shrieve DC, Gutin PH, Larson DA. Brachytherapy. In: Mauch PM, Loeffler JS, eds. Radiation Oncology: Technology and Biology. Philadelphia, PA: WB Saunders Co; 1994. p. 216-36.

Gutin PH, Phillips TL, Wara WM, Leibel SA, Hosobuchi Y, Levin VA, et al. Brachytherapy of recurrent malignant brain tumors with removable high-activity iodine-125 sources. J Neurosurg. 1984;60(1):61-8. doi: 10.3171/jns.1984.60.1.0061.

Selker RG, Shapiro WR, Burger P, Blackwood MS, Arena VC, Gilder JC, et al. The Brain Tumor Cooperative Group NIH Trial 87-01: a randomized comparison of surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy, and carmustine. Neurosurgery. 2002;51(2):343-55.

Laperriere NJ, Leung PM, McKenzie S, Milosevic M, Wong S, Glen J, et al. Randomized study of brachytherapy in the initial management of patients with malignant astrocytoma. Int J Radiat Oncol Biol Phys. 1998;41(5):1005-11. doi: 10.1016/ s0360-3016(98)00159-x.

Suchorska B, Ruge M, Treuer H, Sturm V, Voges J. Stereotactic brachytherapy of low-grade cerebral glioma after tumor resection. Neuro Oncol. 2011;13(10):1133-42. doi: 10.1093/ neuonc/nor100.

Schwarz SB, Thon N, Nikolajek K, Niyazi M, Tonn JC, Belka C, et al. Iodine-125 brachytherapy for brain tumours--a review. Radiat Oncol. 2012;7:30. doi: 10.1186/1748-717x-7-30.

Kickingereder P, Hamisch C, Suchorska B, Galldiks N, Visser-Vandewalle V, Goldbrunner R, et al. Low-dose rate stereotactic iodine-125 brachytherapy for the treatment of inoperable primary and recurrent glioblastoma: single-center experience with 201 cases. J Neurooncol. 2014;120(3):615- 23. doi: 10.1007/s11060-014-1595-y.

Shahzadi S, Azimi P. Stereotactic interstitial iodine-125 brachytherapy for treatment of brain tumors. Int Clin Neurosci J. 2017;4(2):37-8.

Atalar B, Choi CY, Harsh GRt, Chang SD, Gibbs IC, Adler JR, et al. Cavity volume dynamics after resection of brain metastases and timing of postresection cavity stereotactic radiosurgery. Neurosurgery. 2013;72(2):180-5. doi: 10.1227/ NEU.0b013e31827b99f3.

Petr MJ, McPherson CM, Breneman JC, Warnick RE. Management of newly diagnosed single brain metastasis with surgical resection and permanent I-125 seeds without upfront whole brain radiotherapy. J Neuro Oncol. 2009; 92(3):393- 400.

Duggan DM. Improved radial dose function estimation using current version MCNP Monte-Carlo simulation: model 6711 and ISC3500 125I brachytherapy sources. Appl Radiat Isot. 2004;61(6):1443-50. doi: 10.1016/j.apradiso.2004.05.070.

Sarrut D, Bardiès M, Boussion N, Freud N, Jan S, Létang JM, et al. A review of the use and potential of the GATE Monte Carlo simulation code for radiation therapy and dosimetry applications. Med Phys. 2014;41(6):064301. doi: 10.1118/1.4871617.

Jiang H, Seco J, Paganetti H. Effects of Hounsfield number conversion on CT based proton Monte Carlo dose calculations. Med Phys. 2007;34(4):1439-49. doi: 10.1118/1.2715481.

Schneider W, Bortfeld T, Schlegel W. Correlation between CT numbers and tissue parameters needed for Monte Carlo simulations of clinical dose distributions. Phys Med Biol. 2000;45(2):459-78. doi: 10.1088/0031-9155/45/2/314.

XMedCon- An open source toolkit for medical image conversion. Annual Congress of the European Association of Nuclear Medicine - EANM’03; August 23-27; Amsterdam, The Netherlands; 2003.

  • Abstract Viewed: 402 times
  • PDF Downloaded: 466 times

Download Statastics